Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients.
Ramona CassinAndrea VisentinDiana GiannarelliAlessandro NotoFrancesca Romana MauroLuca BaldiniLivio TrentinGianluigi RedaPublished in: Hematological oncology (2020)